Callouts & quotes from 10,384+ activist slides

"The meta-analysis included 11 studies comprising 4,241 participants. Their mean age was 62.56 ± 3.92 years, and 28% of the patients were females. The pooled sensitivity and specificity of the Apple Watch for detecting AF were 94.8% (95% CI: 91.7% to 96.8%; I² = 67%) and 95% (95% CI: 88.6% to 97.8%; I² = 88%), respectively. The area under the receiver operating characteristic curve was 0.96 (95% CI: 0.92-0.97). — Journals of the American College of Cardiology (January 2025)"

"In the announced tender offer, counterparties after the privatisation of Toyota Industries are expected to repurchase their shares [...] with the majority of tax deduction benefit going to counterpart. — UBS, November 20, 2025; The bidders – with the assistance of TICO – are effectively hiding [...] the uplift gained from selling the shares back to the other companies at a discount via Tender Offers which get a different tax treatment [...] — Travis Lundy, January 14, 2026"

""Jamie was an exceptional partner to me for many years, especially when I promoted him to operations chief at CSX. He was a driving force behind our operational transformation into a top-performing rail, thanks in large part to him successfully implementing operational improvements that were critical to generating strong efficiencies. He is one of the best operators I've seen in the rail industry, and any Class I would be fortunate to have him as COO." — The late Jim Foote"

"“So we're in the early innings of what we can do from both PRO and Design... we call it a boots on the ground $25 gift card, give them a bucket, give them the tour of the store, talk about all the things we do.” — Citi, Dec 8, 2021. “And we see people on personal and social media all the time... buying golf clubs or taking their people -- taking their family and friends on cruises or getting gift cards to their clients and their associates.” — Stephens Conf., Nov 18, 2020."

""We think that this business -- that parts of this business are very attractive from a growth basis. There's tremendous synergy with our existing business." — Peter Huntsman, President & CEO, February 2006; "When you look at this [Textile Effects], just kind of this box of chemistry, where there is overlap, there is synergy and so forth, textile effects, it's kind of somewhat outside of that, we don't share a common chemistry..." — Peter Huntsman, President & CEO, May 2016"

""Our policy is that we would only have an arrangement of a 100% subsidiary in the case purely when the subsidiary company's management and employees strongly desired it, and there is no change in our policy in this regard." — Mr. Nagamori (FY 2009 results call). "We had, in the past, explained that it would not be a positive thing for us to continue a situation whereby both the parent company and the subsidiary of that company remain listed." — Mr. Nagamori (FY 2012 Call)."

"As a result of the successful scaling of the Titanium Pilot Facility - and the strong interest we are seeing from potential customers for our 100% recycled, lower cost and low carbon powders - we are now progressing the development of a larger scale facility. This comes at a time when there is an increased strategic focus on the need for wrestling control of the titanium supply chain from China and Russia and bring it back to the U.S. — IperionX Press Release (March 2022)"

"What they're testing is a single-layer lithium anode battery at 45C, and that's important because 45C is not room temperature. As you can guess, there are some benefits to going higher in the temperature. The battery performs more favorably. It also can discharge and recharge more favorably at 45C versus room temperature...what is going to get the battery to that temperature? Are they putting a heater or something in the car in order to provide that? — Former R&D employee"

""Continued weak results show an inability to manage costs and successfully implement sales-building initiatives...our expectation investors will nominate new board members that can provide a fresh perspective on strategic options" — Chris O'Cull, Keybanc, 2/7/17; "Dear Sally...BWLD is on the Hedgeye Restaurant Best Ideas List as a LONG...for all the wrong reasons...Overall, your management team came across as nervous, clueless and weak." — Howard Penney, Hedgeye, 10/17/16"

"They should have known better. I don't know if it fringes on gross negligence, but I still see it to this day...it's still your responsibility. So, they should have known better. And that takes me back to who's running the shop and what's their background, how do they not know, why are they thinking this? There's always a why; sometimes you might never know what that why is, but something's off. — Spruce Point Interview with Medical Device Regulatory Consultant, June 2025"

"“Our top priority is to reassure our patients….” “St. Jude Medical stands behind the security and safety….” “St. Jude Medical will remain ever vigilant and dedicated….” “…..are not aware of such threats and will remain vigilant to the…..” “We recognize the importance of providing physicians with up-to-date and accurate information in a timely and responsible manner…” “Patient safety has always been our top priority and we have every reason to believe….” — St. Jude Medical"

"“Oh, God...I don't know how much success they're going to have with insurance covering these medications”; “I think one person told me about the news of the release of the FDA approval...but that's really about it”; “I would probably wait and see at this point...obviously, if they already have a baseline, poorly controlled diabetes, it probably wouldn't be the best idea. I would be willing to try it, but with hesitancy.” — Endocrinologist at Massachusetts General Hospital"

"“But with Wakix, it doesn't really have any significant signal in terms of changing blood pressure or heart rate. I've been very comfortable adding it right on top. So, that's actually been very useful as well... I've only run an EKG on one such patient because of that..the QT prolongation, I don't think, is something that clinicians are particularly concerned about if they're familiar with QT prolongation.” — Neurologist in Texas, one of largest sleep practices in the US"

"Traditional SCS therapy is a long-established pain treatment that utilizes low frequency stimulation... Paresthesia is often considered unpleasant or uncomfortable, sometimes causes a shocking or jolting sensation with changes in posture and is a continuous reminder of the patient's chronic condition [...] Our HF10 therapy is designed to overcome many of the limitations of traditional SCS therapy, offering benefits to patients, physicians and hospitals. — Nevro S-1 filing"

""In July 2016, the Company's office in London was closed in connection with worldwide group restructuring efforts to reduce loss-making activities. Effective December 1, 2016, the Company ceased it's primary trading activities. The Company is now in the process of winding down its affairs will continue to wind down during the course of 2017. It is expected that all final corporate matters will be formally resolved by September 30, 2018" — Morinda UK Ltd. financial records"

"Simultaneously, the company has opened its Center for AI and Quantum Computing Excellence at 9040 Roswell Road in Sandy Springs, Georgia—a state-of-the-art, Class A eight-story glass office building spanning 180,000 square feet on 23 wooded acres along the Chattahoochee River. Featuring modern high-speed infrastructure and on-site data centers, the lab is optimized for advanced computing with 22,000-square-foot floor plates ideal for collaborative R&D — DVLT Press Release"

"I think it's tricky with their technology...prostate cancer grows in the peripheral zones of the prostate...I'd worry about rupturing the prostate or even worse, potentially injuring structures right outside of the prostate and adjacent to the prostate, specifically the rectum...I think from a logical perspective, it does not make sense to use Aquablation for prostate cancer or focal therapy for prostate cancer. — Tegus Interview with Private Practice Urologist, Dec 2024"

""...in 2019, you laid out a similar cost-cutting program, and it actually looks like costs increased over that period on an absolute basis, stripping out energy and maintenance costs on a per unit - on a per barrel basis and relative to peers. So to instill some confidence maybe in this program that you're about to embark on, can you discuss maybe what went wrong in that 2019 to 2022 program and how you expect to maybe not incur those same issues?" — Cowen, November 2022"

""They now are charging people on a daily basis. So if you think about where the money is in the pyramid, and there's more people at the bottom of the pyramid, especially in some of these developing markets, a lot of poor, lower middle class people. They're creating the opportunity for them to have that access to the Herbalife experience. That's what's driving very strong growth in these markets." — CFO Rich Goudis, Herbalife Bank of America Consumer Conference, 9/12/2009"

""Why don't we take ads? I think the format of ads on mobile phones is not mature yet. Furthermore, there is a fundamental conflict between our safety service, by its very nature, and the advertising model. If you want to target ads accurately, there will be privacy issues." — Yu Lin, NQ founder and chairman. "Q1 is typically seasonally lower in enterprise and advertising. Yet we are seeing continued strength in these businesses, sequentially." — Omar Sharif Khan, Co-CEO."

"“...in the past two years it was the population of the N5 node...that was most of it...now it's N3 and N2...they're delaying those PO's.” — KLA; “the Lasertec tool is not 95% reliable...the mask shop...that's where more of the money is...inspecting in process in the wafer fab - the importance is lower than the mask shop...that's why spending money on an EUV actinic inspection in a wafer fab seems unlikely to me...it would be lower priority overall.” — EUV industry expert"

""By law, over the counter and generic drugs must be similar to their brand name counterparts," certified financial planner Reshell Smith told Business Insider. "The FDA says these drugs are required to have the same active ingredients, strength and dosage as the brand name. Consumers can take comfort in using Equate brand medications as they tend to be regulated by law and the effects of the medication should be equal to the name brand." — Reshell Smith, Business Insider"

"“Before I speak about guidance, a few words on the adoption of ASC 606.... at this point, we don't expect a material impact. In that regard, while we will be providing 2018 financial data in both ASC 606 and ASC 605, we elected to provide guidance for Q1 2018 and the full-year 2018 using the accounting standard ASC 605. We chose to do this to provide better transparency and comparability to 2017 financial data, which was reported in ASC 605.” — NICE Q4 FY17 Earnings Call"

"“...in 2019, you laid out a similar cost-cutting program, and it actually looks like costs increased over that period on an absolute basis, stripping out energy and maintenance costs on a per unit - on a per barrel basis and relative to peers. So to instill some confidence maybe in this program that you're about to embark on, can you discuss maybe what went wrong in that 2019 to 2022 program and how you expect to maybe not incur those same issues?” — Cowen, November 2022"

"“So, I really think the government is going to come in, and they're really going to shake this up, and I think the glory days of we're going to charge $100,000 for a TransMedics device, and you have to use our people, and you've got to use our expensive jet - I think all that is over. I think the gravy train is coming to an end, honestly. I think the government is going to really come in.” — CEO of a major OPO (Organ Procurement Organization), longtime industry executive"

"The CARES Act also enabled us to defer our federal and some state income tax payments from the second quarter of fiscal 2020 to the third quarter of fiscal 2020 and also to defer payment of the employer portion of social security taxes for the balance of fiscal 2020. For the three and six months ended July 3, 2020, we deferred $48 million of employer social security tax payments and received $10 million from the Employee Retention Credit. — Q2 2020 Press Release And 10-Q"

"“In December 2020, we entered into a 12-year operating lease for an approximately 111,000-square foot facility in Wilsonville, Oregon [...] We will pay an initial annual base rent of approximately $1.7 million [...] We have been provided a tenant improvement allowance of $13.3 million [...] The landlord will provide a tenant improvement allowance in connection with our improvements to the additional premises of approximately $4.3 million.” — Twist 10K filed Nov 23, 2021"

"“Our heart transplant group was using it because they might not have a procurement surgeon available to go get a heart. It's not like anything required the device but they would use TransMedics out of convenience, which is a very expensive backup plan if you don't have a surgeon. We've since remedied that. We no longer have any issues with covering the procurement schedule, but for a while, we were using it even when it wasn't clinically indicated.” — UCSF administrator"

"In July 2016, the Company’s office in London was closed in connection with worldwide group restructuring efforts to reduce loss-making activities. Effective December 1, 2016, the Company ceased it’s primary trading activities. The Company is now in the process of winding down its affairs will continue to wind down during the course of 2017. It is expected that all final corporate matters will be formally resolved by September 30, 2018 — Morinda UK Ltd. financial records"

"“When our [Marvell senior executive - title redacted] went to go visit, they were trying to also offer additional A150’s that they had on the books that weren’t, let’s say, being taken ownership of by other competitors that had presumably forecasted that they needed them. And so, we were getting a reduced price as well if we wanted to purchase additional A150s and that price was closer to about, in the range of $15 to 30 million.” — Senior employee at Marvell Technology"

"“When our [Marvell senior executive - title redacted] went to go visit, they were trying to also offer additional A150’s that they had on the books that weren’t, let’s say, being taken ownership of by other competitors that had presumably forecasted that they needed them. And so, we were getting a reduced price as well if we wanted to purchase additional A150s and that price was closer to about, in the range of $15 to 30 million.” — Senior employee at Marvell Technology"

"“When our [Marvell senior executive – title redacted] went to go visit, they were trying to also offer additional A150’s that they had on the books that weren’t, let’s say, being taken ownership of by other competitors that had presumably forecasted that they needed them. And so, we were getting a reduced price as well if we wanted to purchase additional A150s and that price was closer to about, in the range of $15 to 30 million.” — Senior employee at Marvell Technology"

"“When our [Marvell senior executive - title redacted] went to go visit, they were trying to also offer additional A150’s that they had on the books that weren’t, let’s say, being taken ownership of by other competitors that had presumably forecasted that they needed them. And so, we were getting a reduced price as well if we wanted to purchase additional A150s and that price was closer to about, in the range of $15 to 30 million.” — Senior employee at Marvell Technology"

"If you talk about the CT scan machine, so in Hadassah it's Philips company. I don't know or think that this product is in use at hospitals in [I]srael.. I can ask at Hadassah the doctors or tecnitions [sic] about it. Because it's not my department. Like I told you I'm in Intervention Radiology at angiography. We do procedure's [sic] like embolization of bleeding, drainage, chemoemboliation [sic] of tumors, fixing vessels, stenting, etc. — An X-ray technician at Hadassah"

"Party A will provide specializing training to the managers and instructors who hold positions at Party B, and in order to improve their management and operations, will provide additional follow-on training, the guidance Party A will provide to the staff of Party B shall take three forms. 1. Remote video conference call, 2. Visits to Party B to provide management guidance, 3. Visits by Party B’s teachers to Party A’s schools to observe and learn. — Contractual Agreement"

""We are working to improve the reliability and performance of our solid-state separator, including decreasing the thickness." — QuantumScape 10K. "We are likely to encounter engineering challenges as we increase the dimensions, reduce the thickness and increase the volume of our solid-state separators. If we are not able to overcome these barriers in developing and producing its solid-state separators at commercial volumes, our business could fail." — QuantumScape 10K."

"“In our view, Saputo has not carved out an economic moat due to consolidation among dairy producers, which have amassed greater control over the price of raw milk. Further, we believe the lack of differentiation between its products and those of branded competitors and private label doesn’t suggest the existence of a brand intangible asset.” — Morningstar, Saputo Looks to Milk Inflationary Benefits, But Its Position Could Sour on a Lack of Differentiation, Aug 16, 2022"

"It’s all a question of what Time Inc.’s revenue growth potential is and how they see their business model evolving, and how stable are Time Inc.’s revenues going forward...Can Time Inc. be a killer brand online? If not, they’d better figure out ways to harvest cash from cost-cutting...the Company’s publishing division was among the least integrated with TWX’s online businesses, especially AOL — Richard Greenfield, Fulcrum Global Partners (quoted in The New York Times)."

"“...they don't know true B2B sales, they don't do it. That's a totally new area. QuickBooks is a B2B product, but all the companies historically have been so small, it's sold B2C. Most people don't talk to a human. They come to the website, and they enroll...All of a sudden, you want to compete against NetSuite and Microsoft and sell software that will be tens of thousands of dollars a year, that's aspirational, that's not reality.” — Former VP at Intuit, Tegus, 9/8/23"

"「サムスンがレーザーテック製の極端紫外線装置を初めて購入したのはわりと早かったですよ。初めて発注したのは2019年でした」; 「サムスンが持っている極端紫外線露光装置は昨年末（2022年末）の時点で48台だったと思います。私が持っている数字によると、2020年に25台、2021年に34台、2022年に48台となっています。サムスンはそれに合わせてレーザーテック製のACTIS A150を9台持っています。また、（マスクブランクス検査用の）ABICSを9台持っています」; 「それはさきほど言った48台の極端市が線露光装置に合わせて持っています。また、今年（2023年）は極端紫外線露光装置をさらに15台買うから、レーザーテック製のACTISとABICSをそれぞれ約3台追加するでしょう」; 「はい、だからこれらの数字を持っています。また、インテルもACTIS装置1台につき4000万ドルを支払っていたことを知っています」 — サムスンで極端紫外線事業の担当としてレーザーテックと密接な関係を持ち、検査装置の購買について決定権を握っていた、元幹部"

"In fiscal year 2019, the regular annual LTI grant was delayed until the completion of the Transaction. The transaction closed late in fiscal year 2019, resulting in this award being granted after the end of fiscal year 2019. Given the timing of the grant, the award will have a two year vesting period rather than the standard three year vesting period. This award will be disclosed alongside the fiscal year 2020 LTI grant in the 2020 report. — Amcor proxy statement p, 20"

"“Going from 30x30mm, Airpods size, to a bigger size; that's more surface area, more area for a dendrite or a pinhole. Pinhloes are a big issue in ceramics... when you're doing something that's so thin over that big of a form factor, it makes an irregular shape, or it shrinks too much in certain areas.” — Former R&D employee; “Imagine if there's even a particle of dust that gets onto the surface... Those pinholes will instantly short the battery.” — Former R&D employee"

"“PG is working on how to fine tune the Modus Operandi to create ‘more End to End’ that in reality is still a highly matrixed operation with plenty of shared services and shared accountability. This leads to a very long time for decisions to be made as many people need to input... Several people at the General Manager level have confirmed to me that while there is a push for change it all feels in reality ‘business as usual’” — Recently Retired GBU President, July 2017"

""The notion that a decade from now, universities are going to be paying half or two-thirds of their revenue for some marketing and tech services is ridiculous." — John Katzman, founder of Noodle Partners and 2U; "It amazes me that higher education leaders would chose to partner with an OPM like 2U. 2U demands that their university partners use the 2U LMS [Learning Management System] platform and this is NOT an advantage." — A Tipping Point for OPM?, Insidehighered.com"

"For example, the company that makes one of the 10 most common drugs in these categories raised that drug's price 20 percent in the last 12 months. That particular drug, in 2015, cost $11,500 per month. Under Medicare Part D, that means seniors using the drug will typically owe an extra $115 every month. They just went from paying $575 per month to $690 per month, at a time when the average Social Security check is $1,400. — Alex Azar, Remarks on Drug Pricing Blueprint"

"“We are thirty-two year old company. I think that's incredibly important for a multi-level marketing sales company. Longevity is an indication of credibility. There are companies that get in the industry that have rapid growth and decline. It's called a pop and drop. They have a rapid growth and then decline quickly also. So, that longevity is an important point for investors from a confidence standpoint into the business model.” — John DeSimone, Herbalife CFO, 9/6/12"

""Heska's climbed to the top of the innovation and value creation chain. Heska now leads in product breadth, features, benefits, competitiveness and satisfaction." — Wilson at Investor Day November 2020; "Our reliance on less controllable third-party engaged lines is now greatly reduced in relative impact. We control our own performance through our own good work." — Wilson at Investor Day November 2020; "We are a fully transformed company..." — Q4 2020 Earnings Release"

"on 30 November 2023 bp announced that it had agreed to acquire the remaining 50.03% of Lightsource bp. The transaction is expected to close in the second half of 2024, subject to regulatory approvals. As such, bp currently continues to hold a minority equity position in the Lightsource bp joint venture. Therefore, questions in respect of specific Lightsource bp assets, should be directed to Lightsource bp and not bp — BP, the Company's Secretary Office, April 23, 2024"

"people are more likely to complain than to talk about the good things...we’re 8 weeks in with no changes, good or bad; it’s totally understandable this would be a forum where people are mostly raising concerns; I have invested well over 6 years of our lives into this study, so I apologize if I come off a little rude...this medication is not going to work for everyone...it is NOT a cure...there are SO MANY reasons why one would withdraw...ugh.... — Facebook group users"

"L3 primarily challenges the agency's evaluation of proposals under the production and deployment capability factor. With respect to L3's proposal under the factor, TSA rated the proposal as acceptable, based on one evaluated strength, no evaluated weaknesses or deficiencies, and one evaluated risk, which the agency viewed as presenting moderate to high risk to the government. — Government Accountability Officer, In the Matter of L3 Security and Detection Systems, Inc."

"“There is another board-certified sleep specialist. This guy is a complete—forgive my language—whore when it comes to the pharma industry... Their number-one prescriber, number one in the United States, is a friend of mine... We hang out socially and so forth. His name is [redacted]. I would call it to him and say it to his face. Feel free not to quote me on it, but he's a complete whore when it comes to the industry.” — Ex-Harmony territory manager for a large region"

"“We have covered tech/software for 18 years and have never come across a company that is a leader in a $40B TAM and continues to mis-execute so badly. The commentary every quarter of ‘strong demand’, ‘sales productivity/enablement improvements’ and ‘solid momentum’ in the business have not correlated with decelerating growth across all metrics for a number of quarters. It is also amazing to us the Board of Directors has done nothing to push the issue.” — Craig-Hallum"

"“The pressure, 3.4 atmospheres - for sure they have liquid in their battery. It's not all solid-state. Because in solid-state, it cannot work [at 3.4]. We have many, many scientists that worked on this pressure control problem. At room temperature with 3 or 4-atmosphere pressure, there has to be liquid. It's impossible, without high pressure like 20 atmospheres - they cannot ensure contact between the electrolyte and the lithium metal.” — Solid-state batteries expert"

"“The Company is prioritizing chicken and beef offerings, as we expect they represent the largest growth opportunities” — MCD Annual Report. “The U.K. continues to be one of our strongest performing markets. In the first quarter performance in the U.K. was fueled by sustained digital momentum and strong menu initiatives like the national rollout of McPlant and the extremely successful Chicken Big Mac promotion.” — McDonald's Q1 2022 earnings call transcript (4/28/22)."

"WD-40 upgraded to Buy from Neutral at DA Davidson. DA Davidson analyst Linda Weiser upgraded WD-40 to Buy from Neutral with a price target of $225, up from $194. The analyst is citing the company's more attractive valuation following an 8% decline in the stock price from March highs. Weiser adds that if oil prices stay depressed for 60 days, WD-40 could see gross margin upside surprises in the second half of the year along with the expansion of its multiple. — TheFly"

"Currently a significant segment of patients, approximately 40%, are not eligible to receive ruxolitinib [JAKAFI] due to progression on treatment or low platelet counts. These patients would be available immediately at launch for treatment with fedratinib. We believe fedratinib represents a significant opportunity for patients and has the potential to be a billion-dollar blockbuster for Celgene. — Nadim Ahmed, Celgene President of Hematology and Oncology, January 2018"

"Firstly, we do not intend to pursue synergies through a reduction in sales and marketing or R&D costs. — Amcor Deal Call Aug 6, 2018; There's no fundamental change in our level of R&D spending. It's on the contrary; if anything, we've probably spent a bit more. — Amcor FY Earnings Call CEO Sept 6, 2018; Firstly, the R&D infrastructure that will really help us turbocharge the product development efforts is a little bit uneven. — Amcor FY Earnings Call CEO Nov 19, 2019"

"However, eGates, we think of eGates as the turns a mixture between the boarding gate reader to board the airplane and something along the turnstile of the metro, the subway, I don't know if you told TSA, if Congress mandated to TSA to put eGates, I don't know that that's what they would come up with. I think what they would come up with is the eGates that the European immigration lines use, which are complete. I don't know if you've seen them. — Former CLEAR Employee"

"And based on what I know about CLEAR and some of the issues that they face just from a technical perspective and an engineering perspective, is that their tech is never actually ready. And so again, you look at what changes have they made to the product experience prior to this EnVe pod situation over the course of five, seven years, with the exception of changing the colors from that blue to the navy blue that it is now, they've done nothing. — Former CLEAR Employee"

"“I think cynical, in general, just because again, but really struggling because it is the only FDA-approved drug. The families are definitely excited. I’ve talked to several physicians who have written prescriptions. None of them have gotten approved yet... they’re worried that mom-and-pop PCP’s and don’t know a ton about this are going to be prescribing it without maybe some of the safeguards in place.” — KOL in the PWS field; involved with Soleno’s clinical program"